¼¼°èÀÇ Àẹ °áÇÙ °¨¿° °¨Áö ½ÃÀå
Latent Tuberculosis Infection Detection
»óǰÄÚµå : 1774974
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 464 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è Àẹ °áÇÙ °¨¿° °¨Áö ½ÃÀåÀº 2030³â±îÁö 22¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 18¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â Àẹ °áÇÙ °¨¿° °¨Áö ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 3.6%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 22¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ QFT Ç÷¯½º ºê·£µå´Â CAGR 3.0%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 14¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ºê·£µå ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 4.7%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 4¾ï 8,760¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 6.6%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Àẹ °áÇÙ °¨¿° °¨Áö ½ÃÀåÀº 2024³â¿¡ 4¾ï 8,760¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 4¾ï 4,110¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 6.6%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 1.5%¿Í 2.8%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.1%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ Àẹ °áÇÙ °¨¿° °¨Áö ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Àẹ °áÇÙ °¨¿°(LTBI)À̶õ ¹«¾ùÀ̸ç, ¿Ö Á¶±â¹ß°ßÀÌ Áß¿äÇѰ¡?

Àẹ °áÇÙ °¨¿°(LTBI)Àº °áÇÙ±Õ¿¡ °¨¿°µÇ¾úÀ¸³ª Ȱµ¿¼º Áõ»óÀ̳ª Áúº´ÀÇ Â¡Èİ¡ ³ªÅ¸³ªÁö ¾ÊÀ» ¶§ ¹ß»ýÇϸç, LTBI ȯÀÚ´Â Àü¿°¼ºÀÌ ¾øÁö¸¸, ƯÈ÷ ¸é¿ª·ÂÀÌ ÀúÇÏµÈ °æ¿ì Ȱµ¿¼º °áÇÙÀ¸·Î ¹ßÀüÇÒ À§ÇèÀÌ ÀÖ½À´Ï´Ù. LTBIÀÇ Á¶±â ¹ß°ß°ú Ä¡·á´Â ½É°¢ÇÑ °Ç°­ ÇÕº´ÁõÀ» À¯¹ßÇÏ°í ´Ù¸¥ »ç¶÷¿¡°Ô Àü¿°½Ãų ¼ö Àִ Ȱµ¿¼º °áÇÙÀ¸·ÎÀÇ ÁøÇàÀ» ¸·±â À§ÇØ ¸Å¿ì Áß¿äÇϸç, LTBIÀÇ Áø´ÜÀº º¸Åë ÇǺΠ°Ë»ç³ª Ç÷¾× °Ë»ç¸¦ ÅëÇØ ü³» °áÇÙ±ÕÀÇ Á¸À縦 °¨ÁöÇÏ´Â ¹æ½ÄÀ¸·Î ÀÌ·ç¾îÁý´Ï´Ù.

¼¼°è °áÇÙ ¹ßº´·ü Áõ°¡, ƯÈ÷ ÀÇ·á ÀÎÇÁ¶ó°¡ ¿­¾ÇÇÑ ½ÅÈï±¹¿¡¼­ÀÇ °áÇÙ ¹ßº´·ü Áõ°¡´Â ÷´Ü LTBI °ËÃâ ¹æ¹ý¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±âÁ¸ÀÇ ÇǺΠ°Ë»ç°¡ Ç¥ÁØÀ̾úÀ¸³ª, ÀÎÅÍÆä·Ð-¥ã ¹æÃâ ÃøÁ¤¹ý(IGRA)°ú °°Àº »õ·Î¿î Ç÷¾× ±â¹Ý °Ë»ç´Â ³ôÀº Á¤È®µµ¿Í ºü¸¥ °á°ú Á¦°ø ´É·ÂÀ¸·Î Àα⸦ ¾ò°í ÀÖÀ¸¸ç, LTBIÀÇ Á¤È®ÇÑ °ËÃâÀº °áÇÙÀÇ È®»êÀ» ¾ïÁ¦Çϰí Ȱµ¿¼º °áÇÙ ¹ßº´À» ¿¹¹æÇϱâ À§ÇÑ Ä¡·á¸¦ Àû½Ã¿¡ ½ÃÀÛÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. Àû½Ã¿¡ Ä¡·á¸¦ ½ÃÀÛÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù.

Áø´Ü ±â¼úÀÇ ¹ßÀüÀº LTBI °ËÃâ ½ÃÀå¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?

Áø´Ü ±â¼úÀÇ ¹ßÀüÀ¸·Î °áÇÙ±Õ °ËÃâÀÇ Á¤È®¼º, ¼Óµµ, Á¢±Ù¼ºÀÌ Å©°Ô Çâ»óµÇ¾úÀ¸¸ç, PCR ±â¹Ý °Ë»ç¿Í °°Àº ºÐÀÚÁø´Ü¹ýÀº °áÇÙ±ÕÀ» Á¶±â¿¡ °ËÃâÇϱâ À§ÇØ »ç¿ëµÇ°í ÀÖÀ¸¸ç, ±âÁ¸ ¹æ¹ý¿¡ ºñÇØ ´õ ºü¸¥ °á°ú¿Í ³ôÀº ¹Î°¨µµ¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ÈÞ´ë¿ë ¹× ÇöÀå Áø´Ü µµ±¸ÀÇ °³¹ßÀº ƯÈ÷ ½ÇÇè½Ç ÀÎÇÁ¶ó°¡ ºÎÁ·ÇÑ ¿ø°ÝÁö³ª ÀÚ¿øÀÌ ºÎÁ·ÇÑ È¯°æ¿¡¼­ LTBI °Ë»ç¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» °³¼±Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ÀÇ·á Á¾»çÀÚ, HIV °¨¿°ÀÚ, Ȱµ¿¼º °áÇ٠ȯÀÚ¿Í ¹ÐÁ¢ÇÏ°Ô Á¢ÃËÇÏ´Â »ç¶÷ µî °áÇÙ °íÀ§Ç豺 Áý´Ü¿¡¼­ LTBI¸¦ ½Äº°ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

QuantiFERON-TB °ñµå Å×½ºÆ®¿Í °°Àº »õ·Î¿î Ç÷¾× °Ë»çµµ BCG ¹é½Å Á¢Á¾ ÀÌ·Â µîÀÇ ¿äÀο¡ ¿µÇâÀ» ¹ÞÀ» ¼ö ÀÖ´Â Åõº£¸£Ä𸰠ÇǺΠÅ×½ºÆ®(TST)¿¡ ºñÇØ LTBI¸¦ Áø´ÜÇÒ ¼ö ÀÖ´Â º¸´Ù ½Å·ÚÇÒ ¼ö ÀÖ´Â ¹æ¹ýÀ» Á¦°øÇÔÀ¸·Î½á °¨Áö¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, µðÁöÅÐ °Ç°­ µµ±¸¿Í ¿ø°Ý ÀǷḦ Áø´Ü ÇÁ·Î¼¼½º¿¡ ÅëÇÕÇÔÀ¸·Î½á LTBI °Ë»çÀÇ ¹üÀ§¿Í È¿À²¼ºÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº Ȱµ¿¼º °áÇÙÀ¸·Î ÁøÇàµÉ À§ÇèÀÌ ÀÖ´Â °³ÀÎÀ» ´õ ½±°Ô ½Äº°ÇÒ ¼ö ÀÖ°Ô ÇÏ¿© ±Ã±ØÀûÀ¸·Î Àü ¼¼°è °áÇÙÀÇ ºÎ´ãÀ» ÁÙÀÌ´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

LTBI °ËÃâ ½ÃÀåÀÇ ¼ºÀå ÃËÁø¿äÀÎÀº ¹«¾ùÀΰ¡?

LTBI °ËÃâ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº °áÇÙÀÇ Àü ¼¼°è À¯º´·ü Áõ°¡¿Í º¸´Ù Á¤È®Çϰí È¿À²ÀûÀÎ °ËÃâ ¹æ¹ýÀÇ Çʿ伺ÀÔ´Ï´Ù. °áÇÙÀº ƯÈ÷ ÁßÀú¼Òµæ ±¹°¡¿¡¼­ ¿©ÀüÈ÷ °øÁߺ¸°ÇÀÇ ÁÖ¿ä °ü½É»çÀ̱⠶§¹®¿¡ LTBI¸¦ Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖ´Â ½Å·ÚÇÒ ¼ö ÀÖ°í ºñ¿ë È¿À²ÀûÀÎ Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ƯÈ÷ °áÇÙ ¹ßº´·üÀÌ ³ôÀº Áö¿ªÀ¸·ÎºÎÅÍ Àü ¼¼°è À̹ÎÀÚ Áõ°¡µµ LTBI °ËÁø ¹× Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, °¢±¹ Á¤ºÎ¿Í º¸°Ç±â°üÀÌ ÀáÀçÀû °¨¿°ÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ °áÇÙ ÅðÄ¡ ³ë·ÂÀ» °­È­Çϸ鼭 Á¶±â Áø´Ü°ú Ä¡·á°¡ ´õ¿í Áß¿ä½ÃµÇ°í ÀÖ½À´Ï´Ù. Ç÷¾×°Ë»ç, ºÐÀÚÁø´Ü µî Áø´Ü±â¼úÀÇ ¹ßÀüÀ¸·Î LTBI °ËÃâÀÇ ¼Óµµ¿Í Á¤È®µµ°¡ Çâ»óµÇ¾î °íÀ§Ç豺¿¡ ´ëÇÑ Á¢±Ù¼º°ú °æÁ¦¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. °áÇÙ ÅðÄ¡¸¦ À§ÇÑ Àü ¼¼°è º¸°Ç Ȱµ¿ÀÇ È®´ë¿Í ÀÚ±Ý Áö¿øÀº LTBI °ËÃâÀÌ Àü ¼¼°è °áÇÙ ÅðÄ¡ ÇÁ·Î±×·¥ÀÇ ÇʼöÀûÀÎ ºÎºÐÀ¸·Î ÀÚ¸® ÀâÀ¸¸é¼­ ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

LTBI °ËÃâ ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀº ¹«¾ùÀΰ¡?

LTBI °ËÃâ ½ÃÀåÀÇ ¼ºÀåÀº Àü ¼¼°è °áÇÙ ¹ßº´·ü Áõ°¡, º¸´Ù ½Å¼ÓÇϰí Á¤È®ÇÑ Áø´Ü ¹æ¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, °áÇÙ È®»êÀ» ¹æÁöÇϱâ À§ÇØ LTBI¸¦ °¨ÁöÇϰí Ä¡·áÇÏ´Â °ÍÀÇ Á߿伺¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡ µî ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. °áÇÙ ÅðÄ¡¸¦ À§ÇÑ ¼¼°è º¸°Ç ÇÁ·Î±×·¥ÀÇ È®´ë¿Í Áø´Ü ±â¼úÀÇ ¹ßÀüÀ¸·Î Á¶±â ¹ß°ß ¹æ¹ý¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±¹°æ °£ À̵¿ Áõ°¡¿Í ¿¹¹æÀû °Ç°­°ü¸®ÀÇ Á߿伺ÀÌ °­Á¶µÇ¸é¼­ Àü ¼¼°èÀûÀ¸·Î LTBI °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °¢±¹ÀÌ °áÇÙ ÅðÄ¡¸¦ ÃÖ¿ì¼± °úÁ¦·Î »ï°í ÀÖ´Â °¡¿îµ¥, È¿°úÀûÀÎ LTBI °ËÃâ ¹× °ËÁø¿¡ ´ëÇÑ ¼ö¿ä´Â °è¼Ó Áõ°¡ÇÒ °ÍÀ̸ç, °áÇÙ ÅðÄ¡°¡ ¼¼°è º¸°Ç Ȱµ¿ÀÇ ÃÖÀü¼±¿¡¼­ °è¼Ó À¯ÁöµÉ °ÍÀÔ´Ï´Ù.

ºÎ¹®

ºê·£µå(QFT-Plus ºê·£µå, ±âŸ ºê·£µå), °Ë»ç À¯Çü(tuberculin ÇǺΠÅ×½ºÆ® À¯Çü, ÀÎÅÍÆä·Ð¥ã¹æÃ⠾ÀÌ Å×½ºÆ® À¯Çü), ÃÖÁ¾ ¿ëµµ(Áø´Ü½ÇÇè½Ç ÃÖÁ¾ ¿ëµµ, º´¿ø/Áø·á¼Ò ÃÖÁ¾ ¿ëµµ, Çмú±â°ü ¹× ¿¬±¸±â°ü ÃÖÁ¾ ¿ëµµ), ¿ëµµ(Æó°áÇÙ °¡Á¤ ³» Á¢ÃËÀÚ ¿ëµµ, PLHIV ¿ëµµ, ±âŸ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Latent Tuberculosis Infection Detection Market to Reach US$2.2 Billion by 2030

The global market for Latent Tuberculosis Infection Detection estimated at US$1.8 Billion in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. QFT-Plus Brand, one of the segments analyzed in the report, is expected to record a 3.0% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Other Brands segment is estimated at 4.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$487.6 Million While China is Forecast to Grow at 6.6% CAGR

The Latent Tuberculosis Infection Detection market in the U.S. is estimated at US$487.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$441.1 Million by the year 2030 trailing a CAGR of 6.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Latent Tuberculosis Infection Detection Market - Key Trends & Drivers Summarized

What Is Latent Tuberculosis Infection (LTBI) and Why Is Early Detection Critical?

Latent Tuberculosis Infection (LTBI) occurs when a person is infected with the tuberculosis (TB) bacteria but does not exhibit active symptoms or show signs of disease. People with LTBI are not contagious, but they are at risk of developing active TB, especially if their immune system becomes weakened. Early detection and treatment of LTBI are crucial to prevent the progression to active TB, which can cause serious health complications and be transmitted to others. The diagnostic process for LTBI typically involves skin tests or blood tests that detect the presence of the TB bacteria in the body.

The increasing incidence of TB globally, particularly in developing countries with limited healthcare infrastructure, has spurred the demand for advanced LTBI detection methods. While traditional skin tests have been the standard, newer blood-based tests, such as the interferon-gamma release assays (IGRAs), are gaining popularity due to their greater accuracy and ability to provide quicker results. Accurate detection of LTBI is essential for controlling the spread of TB and for initiating timely treatment to prevent the development of active TB.

How Are Advancements in Diagnostic Technologies Impacting the LTBI Detection Market?

Advancements in diagnostic technologies have significantly improved the accuracy, speed, and accessibility of LTBI detection. Molecular diagnostics, such as PCR-based tests, are increasingly being used to detect TB bacteria at an early stage, providing faster results and greater sensitivity compared to traditional methods. Additionally, the development of portable and point-of-care diagnostic tools is improving access to LTBI testing, particularly in remote or resource-limited settings where laboratory infrastructure may be lacking. These innovations are crucial for identifying LTBI in populations that are at high risk for TB, such as healthcare workers, individuals living with HIV, and those in close contact with active TB patients.

Newer blood tests, such as the QuantiFERON-TB Gold test, are also improving detection by offering a more reliable method for diagnosing LTBI compared to the tuberculin skin test (TST), which can be influenced by factors such as prior BCG vaccination. Furthermore, the integration of digital health tools and telemedicine into the diagnostic process is expanding the reach and efficiency of LTBI testing. These advancements are making it easier to identify individuals who are at risk for progressing to active TB, ultimately helping reduce the global burden of TB.

What Are the Primary Drivers of the LTBI Detection Market's Growth?

The primary drivers behind the growth of the LTBI detection market are the increasing global prevalence of tuberculosis and the need for more accurate, efficient detection methods. As TB remains a major public health concern, particularly in low-income and middle-income countries, there is growing demand for reliable and cost-effective diagnostic tools to identify LTBI early. The rise in global migration, particularly from regions with high TB prevalence, is also contributing to the increased demand for LTBI screening and detection.

Furthermore, as governments and health organizations intensify efforts to eliminate TB by targeting latent infections, there is greater emphasis on early diagnosis and treatment. Advancements in diagnostic technology, such as blood-based tests and molecular diagnostics, are improving the speed and accuracy of LTBI detection, making them more accessible and affordable for high-risk populations. The expansion of global health initiatives and funding aimed at TB eradication is further propelling market growth, ensuring that LTBI detection is an integral part of global TB control programs.

What Are the Key Growth Drivers for the LTBI Detection Market?

The growth in the LTBI detection market is driven by several factors, including the increasing incidence of tuberculosis globally, the rising demand for faster and more accurate diagnostic methods, and growing awareness about the importance of detecting and treating LTBI to prevent the spread of TB. The expansion of global health programs aimed at TB eradication, along with advancements in diagnostic technologies, is providing greater access to early detection methods. Additionally, the increasing movement of people across borders and the greater emphasis on preventive healthcare are also driving the demand for LTBI testing worldwide. As countries continue to prioritize TB control, the demand for effective LTBI detection and screening will continue to grow, ensuring that the fight against tuberculosis remains at the forefront of global health efforts.

SCOPE OF STUDY:

The report analyzes the Latent Tuberculosis Infection Detection market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Brand (QFT-Plus Brand, Other Brands); Test Type (Tuberculin Skin Test Type, Interferon Gamma Released Assay Test Type); End-Use (Diagnostic Laboratories End-Use, Hospitals / clinics End-Use, Academic & Research Institutions End-Use); Application (Household Contacts with Pulmonary TB Application, PLHIV Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â